Toggle Health Problems and D

Ivermectin reduced COVID-19 deaths in Peru by 14X, after new president halted it, the death rate increased 13X – March 18, 2021

Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p=.002 for effect by state, then 13-fold increase after ivermectin use restricted

 Download the Preprint from VitaminDWiki
Juan J. Chamie-Quintero,a Jennifer A. Hibberd,b David E Scheimc


Note: The sections of Peru of getting the most Ivermectin had the biggest declines in excess deaths

COVID-19 treated by Vitamin D - studies, reports, videos

As of April 17 the page had:  34 trials5 trial results,  17 meta-analyses and reviews,   55 observations,   34 recommendations,   53 associations,  86 speculations,  43 videos   see related:   Governments,   HealthProblems,   Hospitals,  Dark Skins,   26 risk factors are ALL associated with low Vit D,   Recent Virus pages   Fight COVID-19 with 50K Vit D weekly

  • Image
    • The above image is automatically updated

Introduction. On May 8, 2020, Peru’s Ministry of Health approved ivermectin (IVM), a drug of Nobel Prize-honored distinction, for inpatient and outpatient treatment of COVID-19. As IVM treatments proceeded in that nation of 33 million residents, excess deaths decreased 14-fold over four months through December 1, 2020, consistent with clinical benefits of IVM for COVID-19 as have emerged in several RCTs. But after IVM use was sharply restricted under a new president, excess deaths then increased 13fold.

Methods. To evaluate possible IVM treatment effects suggested by these aggregate trends, excess deaths were analyzed by state for ages > 60 in Peru’s 25 states. To identify potential confounding factors, Google mobility data, population densities, SARS-CoV-2 genetic variations and seropositivity rates were also examined.

Results. The 25 states of Peru were grouped by extent of IVM distributions: maximal (mass IVM distributions through operation MOT, a broadside effort led by the army); medium (locally managed IVM distributions); and minimal (restrictive policies in one state, Lima).
The mean reduction in excess deaths 30 days after peak deaths was

  • 74% for the maximal IVM distribution group,
  • 53% for the medium group and
  • 25% for Lima. (minimal)

Reduction of excess deaths is correlated with extent of IVM distribution by state with p<0.002 using the Kendall Tb test.

Conclusion. Mass treatments with IVM, a drug safely used in 3.7 billion doses worldwide since 1987, most likely caused the 14-fold reductions in excess deaths in Peru, prior to their 13-fold increase after IVM policy was reversed. This strongly suggests that IVM treatments can likewise effectively complement immunizations to help eradicate COVID-19. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

Created by admin. Last Modification: Thursday March 25, 2021 13:40:23 GMT-0000 by admin. (Version 6)
See any problem with this page? Report it (FINALLY WORKS)